PPARgamma activation improves cardiac energy metabolism in patients with type 2 diabetes Mellitus

PPARgamma activation improves cardiac energy metabolism in patients with type 2 diabetes Mellitus

Bibliographische Detailangaben
Hauptverfasser:	Scheuermann-Freestone, M, Madsen, P, Buckingham, R, Styles, P, Neubauer, S, Clarke, K
Format:	Conference item
Veröffentlicht:	2003

Ähnliche Einträge

Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes.
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2003)

Cardiac and skeletal muscle metabolism after chronic PPAR gamma activation in type 2 diabetes mellitus
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2004)

Abnormal cardiac high-energy phosphate metabolism in a patient with type 2 diabetes mellitus.
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2006)

Effect of chronic peroxisome proliferator-activated receptor gamma (PPAR gamma) activation on cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes mellitus
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2004)

Fatty acid metabolism in patients with PPARgamma mutations.
von: Tan, G, et al.
Veröffentlicht: (2008)

Sleep apnoea is associated with impaired cardiac high-energy phosphate metabolism and abnormal diastolic function
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2006)

Does dieting affect cardiac high-energy phosphate metabolism and cardiac function? Effects of two weeks of a high-fat, low-carbohydrate diet in healthy subjects
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2006)

Abnormal cardiac energetics are associated with diastolic dysfunction in uncomplicated obesity
von: Robinson, M, et al.
Veröffentlicht: (2006)

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.
von: Lygate, C, et al.
Veröffentlicht: (2003)

Abnormal cardiac and skeletal muscle function and energetics correlate with insulin resistance in heart failure
von: Scheuermann-Freestone, M, et al.
Veröffentlicht: (2004)

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.
von: Altshuler, D, et al.
Veröffentlicht: (2000)

Haemoglobin and flow-mediated vasodilation.
von: Madsen, P, et al.
Veröffentlicht: (2006)

PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes.
von: Bagi, Z, et al.
Veröffentlicht: (2004)

Ppargamma2 is a key driver of longevity in the mouse.
von: Carmen Argmann, et al.
Veröffentlicht: (2009-12-01)

Derangement of cardiac high energy phosphate metabolism in patients with left ventricular non-compaction and preserved ejection fraction
von: Petersen, S, et al.
Veröffentlicht: (2006)

Impaired cardiac energy metabolism and diastolic dysfunction in normal subjects after two weeks on a high-fat, low-carbohydrate diet
von: Freestone, MS, et al.
Veröffentlicht: (2005)

PPARgamma regulates trophoblast proliferation and promotes labyrinthine trilineage differentiation.
von: Mana M Parast, et al.
Veröffentlicht: (2009-11-01)

PPARgamma-Dependent Control of Renin Expression: Molecular Mechanisms and Pathophysiological Relevance
von: Vladimir T. Todorov
Veröffentlicht: (2013-01-01)

Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha.
von: Jonathan Goldwasser, et al.
Veröffentlicht: (2010-08-01)

PPARgamma: A Potential Intrinsic and Extrinsic Molecular Target for Breast Cancer Therapy
von: Giuseppina Augimeri, et al.
Veröffentlicht: (2021-05-01)

PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders
von: Grygiel-Górniak B, et al.
Veröffentlicht: (2018-03-01)

The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank.
von: Tan, G, et al.
Veröffentlicht: (2006)

Influence of the body mass and visceral adiposity on glucose metabolism in obese women with Pro12Pro genotype in PPARgamma2 gene
von: Vanessa Chaia Kaippert, et al.
Veröffentlicht: (2013-06-01)

Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus
von: Levelt, E, et al.
Veröffentlicht: (2015)

Hemoglobin and nitric oxide dependent vasodilation
von: Madsen, P, et al.
Veröffentlicht: (2005)

Patients with obstructive sleep apnoea have impaired cardiac metabolism and diastolic dysfunction compared to controls
von: West, S, et al.
Veröffentlicht: (2005)

PPARgamma dependent PEX11beta counteracts the suppressive role of SIRT1 on neural differentiation of HESCs.
von: Maryam Esmaeili, et al.
Veröffentlicht: (2024-01-01)

Exercise training in dilated cardiomyopathy improves rest and stress cardiac function without changes in cardiac high energy phosphate metabolism.
von: Holloway, C, et al.
Veröffentlicht: (2012)

The cardiovascular changes underlying a low cardiac output with exercise in patients with type 2 diabetes mellitus
von: Per Lav Madsen, et al.
Veröffentlicht: (2024-03-01)

Uncomplicated obesity is associated with abnormal aortic function assessed by cardiovascular magnetic resonance.
von: Robinson, MR, et al.
Veröffentlicht: (2008)

Uncomplicated obesity is associated with abnormal aortic function assessed by cardiovascular magnetic resonance
von: Robinson, MR, et al.
Veröffentlicht: (2008)

Uncomplicated obesity is associated with abnormal aortic function assessed by cardiovascular magnetic resonance
von: Robinson, M, et al.
Veröffentlicht: (2008)

Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells
von: Wallis Natalie K, et al.
Veröffentlicht: (2008-12-01)

MCT4-dependent lactate transport: a novel mechanism for cardiac energy metabolism injury and inflammation in type 2 diabetes mellitus
von: Xiu Mei Ma, et al.
Veröffentlicht: (2024-03-01)

Pirfenidone induces epigenetic changes modulating the activity of the ppargamma-SIRT1-DNMT1 axis in hepatic stellate cells
von: H.C. Monroy-Ramírez, et al.
Veröffentlicht: (2020-09-01)

α-mangostin improves glucose uptake and inhibits adipocytes differentiation in 3T3-L1 cells via PPARgamma, GLUT4, and leptin expressions
von: Taher, Muhammad, et al.
Veröffentlicht: (2015)

Mitochondrial Dysfunction as a Factor of Energy Metabolism Disorders in Type 2 Diabetes Mellitus
von: Alexander Blagov, et al.
Veröffentlicht: (2024-03-01)

Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
von: Knowles, H, et al.
Veröffentlicht: (2006)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
von: Davies MJ, et al.
Veröffentlicht: (2017-01-01)

The Impact of Metabolic Syndrome and Type 2 Diabetes Mellitus on Prostate Cancer
von: André P. Sousa, et al.
Veröffentlicht: (2022-03-01)